In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads...
Read More
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads to...
Read More
In a nutshell This study examined if nivolumab is an effective treatment for relapsed and unresponsive Hodgkin lymphoma. This study concluded that nivolumab is an effective treatment for these patients, regardless of previous stem cell treatment status. Some background Standard treatment for patients with Hodgkin lymphoma (HL) which has relapsed or...
Read More
In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...
Read More
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read More
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read More
In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for...
Read More
In a nutshell This trial is examining the safety and effectiveness of mosunetuzumab plus polatuzumab vedotin for B-cell non-Hodgkin’s lymphoma (NHL). The main outcomes to be measured will be the complete response rate and the occurrence of side effects after treatment. This study is recruiting in Miami, Florida, New York City, New York, and Duarte,...
Read More
In a nutshell This study examined the safety and effectiveness of rituximab (Rituxan) to treat relapsed or unresponsive chronic lymphocytic leukemia (CLL) in a real-world setting. Authors concluded that rituximab was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a cancer of the immune system. It...
Read MoreIn a nutshell This study aimed to investigate patient well-being and patient-reported outcomes in previously treated patients with chronic lymphocytic leukemia who receive ibrutinib (Imbruvica) or ofatumumab (Arzerra). They concluded that ibrutinib can improve quality of life while prolonging survival in these patients. Some background...
Read More
In a nutshell This phase 3 trial is investigating the safety and effectiveness of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for mantle cell lymphoma (MCL). The main outcomes to be measured will be survival without cancer growing or spreading and side effects of treatment. The details Mantle cell lymphoma (MCL) is an aggressive type of...
Read MoreIn a nutshell This study looked at the effectiveness of venetoclax-rituximab (Venclexta–Rituxan) in patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). Researchers found that this treatment improved survival in patients with CLL. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. This can...
Read More
